Doesn't necessarily prevent cancer, but seems to help you survive it
By GERMAN CANCER RESEARCH CENTER
Vitamin D deficiency is a widespread global issue and is notably prevalent among cancer patients.
Averaged over the year, the vitamin D blood levels of about 15 percent of
German adults are below the threshold for a pronounced vitamin D deficiency.
Furthermore, a study found that 59 percent of colorectal cancer patients
suffered from a deficiency of Vitamin D3, which also correlated with a poor
prognosis.
The potential effects of vitamin D supplementation and the development or prognosis of cancer have already been investigated in numerous studies. “Based on current studies, vitamin D3 supplementation probably does not protect against developing cancer, but it could reduce the likelihood of dying from cancer.
However, previous studies on cancer mortality have yielded very different results, and we were interested in the reasons for this,” said Ben Schöttker, an epidemiologist at the German Cancer Research Center.
“By re-evaluating all previous studies on
the topic, we wanted to help produce robust results on this issue, which is so
relevant to population health.
To investigate the effectiveness of vitamin D3 on cancer mortality in the population and on the survival of cancer patients, Ben Schöttker and colleagues conducted a systematic literature search that identified 14 studies with a total of nearly 105,000 participants. The researchers considered only studies of the highest quality whose participants had been randomly assigned to the vitamin D3 arm or the placebo arm.
When all 14 studies were pooled, no statistically significant results emerged. However, when the studies were divided according to whether vitamin D3 was taken daily in a low dose or in higher doses administered at longer intervals, a large difference was seen.
In the four studies with the infrequent higher doses, there was no effect on
cancer mortality. In contrast, in the summary of the ten studies with daily
dosing, the researchers determined a statistically significant twelve percent
reduction in cancer mortality.
“We observed this twelve percent reduction in cancer mortality after untargeted vitamin D3 administration to individuals with and without vitamin D deficiency. We can therefore assume that the effect is significantly higher for those people who are actually vitamin D deficient,” says Ben Schöttker.
He explains the better
efficacy of daily doses of vitamin D3 by the more regular bioavailability of
the active agent, the hormone 1,25-dihydroxy vitamin D, which is only produced
by reactions of vitamin D in the body and can presumably inhibit tumor growth.
A more detailed analysis
of the studies with daily intake further revealed that people aged 70 and older
benefited most from vitamin D3 therapy. In addition, the effect was most
evident when vitamin D intake was started before the cancer diagnosis.
Hermann Brenner,
epidemiologist and prevention expert at DKFZ, adds: “This work underlines the
great potential of vitamin D3 administration in the prevention of cancer
deaths. Regular intake at low doses is associated with almost negligible risk
and very low cost.”
Reference: “Efficacy of
vitamin D3 supplementation on cancer mortality: Systematic review and
individual patient data meta-analysis of randomised controlled trials” by
Sabine Kuznia, Anna Zhu, Taisuke Akutsu, Julie E. Buring, Carlos A. Camargo Jr,
Nancy R. Cook, Li-Ju Chen, Ting-Yuan David Cheng, Sari Hantunen, I.-Min Lee,
JoAnn E. Manson, Rachel E. Neale, Robert Scragg, Aladdin H. Shadyab, Sha Sha,
John Sluyter, Tomi-Pekka Tuomainen, Mitsuyoshi Urashima, Jyrki K. Virtanen, Ari
Voutilainen and Ben Schöttker, 31 March 2023, Ageing Research Reviews.
DOI:
10.1016/j.arr.2023.101923
